Structure via PubChem · Public domain (PubChem)
capmatinib
Sign in to saveAlso known as INC280, INCB28060, Tabrecta
Capmatinib, sold under the brand name Tabrecta, is an anticancer medication used for the treatment of metastatic non-small cell lung cancer whose tumors have a mutation that leads to the exon 14 skipping of the MET gene, which codes for the membrane receptor HGFR.
Key facts
- Drug.O
- 1
- Drug.image
- Capmatinib.svg
- Drug.image_class
- skin-invert-image
- Drug.tradename
- Tabrecta
- Drug.MedlinePlus
- a620038
- Drug.DailyMedID
- Capmatinib
- Drug.pregnancy_category
- Not recommended
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- L01
- Drug.ATC_suffix
- EP01
- Drug.legal_CA
- Rx-only
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.CAS_number
- 1029712-80-8
- Drug.PubChem
- 25145656
- Drug.DrugBank
- DB11791
- Drug.ChemSpiderID
- 25069712
- Drug.UNII
- TY34L4F9OZ
via Wikipedia infobox
Chemical data
- Formula
- C23H17FN6O
- Molecular weight
- 412.4 g/mol
- IUPAC name
- 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide
- SMILES
- CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F
- InChIKey
- LIOLIMKSCNQPLV-UHFFFAOYSA-N
- XLogP
- 2.9
- Polar surface area
- 85.1 Ų
- H-bond donors
- 1
- H-bond acceptors
- 6
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2020
- Admin. routes
- oral
- Indications
- non-small cell lung carcinoma, hepatocellular carcinoma, cutaneous melanoma, glioblastoma multiforme
via ChEMBL · EBI
Research
314 papers- Capmatinib.2012
- Capmatinib.2006
- Capmatinib: First Approval.Drugs · 2020
- Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.The New England journal of medicine · 2020
- Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial.The Lancet. Oncology · 2024
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 412.144787
Show 7 more facts
- canonical SMILES
- CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F
- chemical formula
- C₂₃H₁₇FN₆O
- subject has role
- protein kinase inhibitors
- World Health Organisation international non-proprietary name
- capmatinib
- medical condition treated
- non-small-cell lung carcinoma
- physically interacts with
- MET proto-oncogene, receptor tyrosine kinase
- Commons category
- Capmatinib
Sources (6)
via Wikidata · CC0
~5 min read
Encyclopedic overview
8 sectionsContents
- Medical uses
- Adverse effects
- Pharmacology
- History
- Society and culture
- Legal status
- References
- External links
Capmatinib, sold under the brand name Tabrecta, is an anticancer medication used for the treatment of metastatic non-small cell lung cancer whose tumors have a mutation that leads to the exon 14 skipping of the MET gene, which codes for the membrane receptor HGFR.
The most common adverse reactions are peripheral edema, nausea, fatigue, vomiting, dyspnea, and decreased appetite.
Excerpted from Wikipedia’s “capmatinib” article, available under the CC BY-SA 4.0 licence.